Effect of Combination Therapy on Immunologic Progression of Human Immunodeficiency Virus at a Population Level

Parpia, Tamiza; Raab, Gillian M.; Goldberg, David J.; Allardice, G.; McMenamin, Jim; Whitelaw, J; McSharry, Charles; Potts, Robert; Herriot, Richard

doi:10.1093/aje/153.9.898

Cited by 7 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of the effect on all HIV-diagnosed persons have not been found in the literature. The study closest to being a study of all HIV-diagnosed persons has been carried out in Scotland (7).…”

Section: Introductionmentioning

confidence: 99%

“…The lesser effect on progression to AIDS for HIVdiagnosed IDUs is also found in Scotland. In a study by Parpia et al of 95% of patients in medical care for HIV in Scotland, IDUs were less frequently on effective triple/quadruple treatment (6% vs 15% among men infected through sex with men and 10% among persons infected heterosexually) (7). IDUs more frequently had no treatment (35% vs 18% among men infected through sex with men and 32% among persons infected heterosexually).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy

Amundsen

Fekjær

2003

Scand J Public Health

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy

Amundsen

Fekjær

2003

Scand J Public Health

View full text Add to dashboard Cite

show abstract

“…An annual Survey of Prevalent HIV Infections Diagnosed (SOPHID) was introduced in England, Wales and Northern Ireland in 1995 to monitor the number of people accessing treatment and care through the (national) health service [68]. In Scotland, equivalent information is collected through a surveillance system involving the collection of CD4 count data [69]. Improvements in survival and continued diagnoses among gay men have led to increasing numbers living with diagnosed HIV ; 17 932 gay men were accessing services in 2004 compared with 11 846 in 2000 ( Fig.…”

Section: Gay Men Living With Diagnosed Hiv Infection: 1996 Onwardsmentioning

confidence: 99%

HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance

Dougan¹,

Evans²,

MacDonald³

et al. 2007

Epidemiol. Infect.

View full text Add to dashboard Cite

It is more than 25 years since the first case of AIDS was reported in the United Kingdom. In December 1981 a gay man was referred to a London hospital with opportunistic infections indicative of immunosuppression. National surveillance began the following year, in September 1982, with the notification of deaths and clinical reports of AIDS and Kaposi's sarcoma plus laboratory reports of opportunistic infections. Since then epidemiological surveillance systems have evolved, adapting to, and taking advantage of advances in treatments and laboratory techniques. The introduction of the HIV antibody test in 1984 led to the reporting of HIV-positive tests by laboratories and the establishment of an unlinked anonymous survey in 1990 measuring undiagnosed HIV infection among gay men attending sexual health clinics. The widespread use of highly active antiretroviral therapies (HAART) since 1996 has averted many deaths among HIV-positive gay men and has also resulted in a large reduction in AIDS cases. This led to a need for an enumeration of gay men with HIV accessing NHS treatment and care services (1995 onwards), more clinical information on HIV diagnoses for epidemiological surveillance (2000 onwards) and the routine monitoring of drug resistance (2001 onwards). Twenty-five years after the first case of AIDS was reported, gay and bisexual men remain the group at greatest risk of acquiring HIV in the United Kingdom. Latest estimates suggest that in 2004, 26 500 gay and bisexual men were living with HIV in the United Kingdom, a quarter of whom were undiagnosed. In this review, we examine how national surveillance systems have evolved over the past 25 years in response to the changing epidemiology of HIV/AIDS among gay and bisexual men in the United Kingdom as well as advances in laboratory techniques and medical treatments. We also reflect on how they will need to continue evolving to effectively inform health policy in the future.

show abstract

“…The current standard combination antiretroviral therapy (cART) for HIV-1 infection restores the immune function by limiting the progression of the disease [ 1 ]. The introduction of cART in clinical practice significantly reduced HIV-related morbidity and mortality, improving the quality of life (QoL) of people infected with HIV [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

et al. 2016

View full text Add to dashboard Cite

BackgroundAim of the study was to assess predictors of discontinuation/toxicity of boosted PI-based (PI/r) dual therapy (DT).MethodsObservational, retrospective switch study in patients successfully treated with triple drugs regimen. Patients switched to PI/r based DT [darunavir (DRV/r), lopinavir (LPV/r) or atazanavir (ATV/r)] plus a second drug: [raltegravir (RAL), maraviroc (MVC) etravirine (ETR), lamivudine (3TC) or tenofovir (TDF)] between 2009 and 2014 were included. The effect of each drug as well as other clinical and virological cofactors over treatment discontinuation (TD) was assessed using survival analysis.ResultsOverall, 376 patients were included with mean follow-up of 73 weeks. The most commonly used drugs in DT were DRV/r (63.0 %) and RAL (53.7 %). TD was observed in 77 (20,4 %) patients: 38 (10,1 %) virological failure, 35 (9,3 %) toxicity/intolerance (4 deaths) and 4 (1 %) interruptions for patients decision. At Cox Model, adjusted by demographic and laboratory variables, DRV/r and ATV/r significantly reduced the likelihood of TD and longer treatment was associated with lower risk, while low CD4 count at baseline and number of previous regimens with a higher risk. Moreover, RAL and 3TC use were significantly associated with lower TD by toxicity.ConclusionsIn our clinical practice experience, switching virologically suppressed patients to PI/r based DT showed adequate safety and efficacy, so that it may be used in selected patients with specific medical needs.

show abstract

Effect of Combination Therapy on Immunologic Progression of Human Immunodeficiency Virus at a Population Level

Cited by 7 publications

References 12 publications

Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy

Progression to AIDS slowed even more after the first two years with highly active antiretroviral therapy

HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

Contact Info

Product

Resources

About